New Data Shows Colorado’s Bioscience Industry Outpaced National Growth Since 2001 and Continued Adding Jobs Overall Since 2007  

The 26th annual Mountain Desert Region Entrepreneur of the Year awards were presented by Ernst & Young LLP. 

Northern Colorado Business Report-The number of Colorado medical device companies grew by nearly 20 percent in Colorado in the last decade, according to a new bioscience report.  

Supreme Court Affordable Care Act Ruling Must Now Lead to Implementation That Will Promote Innovation and Expand Access, Says BIO 

The Senate voted 92-4 to approve a bill that would authorize the FDA to collect $6 billion in user fees from medical firms to fund the review of drugs and devices. The legislation would extend the program to makers of biosimilars and generic drugs. The FDA estimated that user fees from 2013 to 2017 would pay for approximately 60% of review costs. The legislation now goes to President Barack Obama's desk.   

BiOptix (Boulder) announces the appointment of Michael W. Routh, Ph. D. to the Board of Directors of the firm, adding to a preeminent group of leaders driving BiOptix and its proprietary Enhanced Surface Plasmon Resonance platform toward continued success in the life science marketplace.  

Accelr8 Technology Corporation (Denver) announced the appointment of Lawrence Mehren as President and Chief Executive Officer and a member of the Board of Directors.  Accelr8 also announced that it has received shareholder approval, met all closing conditions, and has consummated a transaction that will result in an investment of up to $35 million in Accelr8’s common stock.  

Biodesix, Inc. (Boulder) announced the presentation of initial results of their proteomic analysis of GlobeImmune’s Phase 2 clinical trial in pancreas cancer at the European Society of Medical Oncology’s, 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain on 27 June 2012.   

GlobeImmune, Inc. (Louisville), announced that GI-4000 in combination with gemcitabine showed evidence of an improvement in overall survival for subjects with Ras mutation positive pancreas cancer with microscopic residual disease after surgery (R1 subjects).